Mach5 Therapeutics
Atlanta, US · Founded 2023 · Delaware corporation
Founders & leadership
PJ
Patrick J. CrutcherNamed on SEC filing
JD
Justin DiMartinoNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$23.4M disclosed across 2 rounds · 2024
▶$19.2MraisedNov 2024 · 15 investors · BiotechnologyRule 506(b)
▶$19.2MraisedNov 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick J. CrutcherExecutive Officer, Director
- Justin DiMartinoExecutive Officer, Director
- Offering amount
- $19.9M
- Amount sold
- $19.2M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$4.2MraisedApr 2024 · 7 investors · BiotechnologyRule 506(b)
▶$4.2MraisedApr 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick J. CrutcherExecutive Officer, Director, Promoter
- Justin DiMartinoExecutive Officer, Director, Promoter
- Offering amount
- $4.5M
- Amount sold
- $4.2M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Mach5 Therapeutics raised?
- Mach5 Therapeutics has disclosed $23.4M raised across 2 rounds.
- Where is Mach5 Therapeutics headquartered?
- Mach5 Therapeutics is headquartered in Atlanta, US.